Compare LFS & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LFS | ENTX |
|---|---|---|
| Founded | 2001 | 2010 |
| Country | Japan | Israel |
| Employees | 1055 | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.7M | 58.2M |
| IPO Year | N/A | 2015 |
| Metric | LFS | ENTX |
|---|---|---|
| Price | $2.05 | $1.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 343.1K | ★ 2.9M |
| Earning Date | 04-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $42,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $25.19 | $28.43 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.58 | $0.91 |
| 52 Week High | $12.49 | $3.22 |
| Indicator | LFS | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.19 | 72.80 |
| Support Level | $1.88 | $1.45 |
| Resistance Level | $2.33 | $2.04 |
| Average True Range (ATR) | 0.13 | 0.16 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 1.82 | 80.77 |
Leifras Co Ltd is a sports and social business company dedicated to youth sports and community engagement. It provide services related to the organization and operations of sports schools and sports events for children. The company focuses on covering 13 sports like soccer, basketball, and dance and in child athletic development, club activity management for schools, and social businesses like elderly care.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.